Core Viewpoint - "如身机器人" has recently completed a multi-million RMB angel round financing, which will be used for core technology iteration, product engineering, pilot projects in elderly care scenarios, and early market deployment [1] Company Overview - "如身机器人" (Shanghai Roushen Robot Technology Co., Ltd.) was established in June 2023, focusing on intelligent robots for smart elderly care, aiming to develop robots that can serve the elderly in home settings [1] - The company targets rehabilitation fitness and home service sectors, emphasizing modularity, cost-effectiveness, and human-robot collaboration [1][5] - The headquarters is located in Zhangjiang, Shanghai, with a European R&D and operations center in Munich, Germany, and a production base in Jiaxing, Zhejiang [1] Team Composition - The founding team includes members from top institutions such as the German Academy of Robotics, listed company MicroPort, and European unicorn Agile Robots [3] - The Chief Scientist is a foreign academician of the Chinese Academy of Engineering, and the CEO, Dr. Shi Yunlei, has over 12 years of interdisciplinary experience in medical robotics [3][5] Product Development - The company has developed a product matrix covering various rehabilitation and home service needs, including four main product lines: "格物", "致知", "修身", and "齐家" [5] - The "格物" series targets home rehabilitation, with its first product, 如身 C1, being the world's first home rehabilitation robot covering all joints of the upper and lower limbs [6][8] - The "致知" series is aimed at community rehabilitation institutions, featuring 如身 B1, a robot with seven degrees of freedom for upper and lower limb rehabilitation [8][10] - The "修身" series focuses on upper limb rehabilitation with the 如身 G1 exoskeleton robot, designed to enhance motor coordination [10][11] - The "齐家" series is dedicated to elderly care, with its main product, 齐家Q1, providing various support functions for semi-disabled and elderly individuals [11][13] Market Position and Future Plans - 如身 C1 has been mass-produced and exported to North America, Europe, and Southeast Asia, with positive user feedback and increasing orders [8] - 如身 B1 has established preliminary cooperation with major hospitals, including Huashan Hospital and Tongji Orthopedic Hospital [10] - 齐家Q1 has completed three iterations and is expected to achieve standardized mass production by 2026 [13] - The company has secured seed and angel round financing from various investors, indicating strong market interest and potential for growth [13]